Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Liquidia Corporation (LQDA)

NASDAQ: LQDA · Pharmaceutical Preparations · Morrisville, NC

Our rating: Positive

Positive reaffirmed at $55.21, moderate conviction, November 11, 2026.

Breaks if: The Positive call breaks if YUTREPIA's implied quarterly revenue run-rate shows two consecutive sequential declines across the next two 10-Q filings — that would signal the launch curve has bent and the 31× sales multiple becomes very hard to defend at any plausible forward revenue estimate. A material adverse patent ruling or label restriction that narrows the addressable population would also invalidate immediately, regardless of where the price sits.

Key figures

Market value$4.9B
Revenue, last 12 months$622M
Net income, last 12 months−$94M
Free cash flow, last 12 months$291M
Price to earningsn/a
Free cash flow yield5.9%
Dividend yield0.0%
Operating margin−15.6%
Return on equityn/a
Beta to the S&P 5001.07
Volatility, annualized76.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$225M314.6%$-2.64$130M
June 30, 2026$172M1842.7%$0.74$69M
March 31, 2026$133M4158.5%$0.52$50M
December 31, 2025$92M3054.6%$0.17$42M
September 30, 2025$54M1121.7%$-0.04−$11M
June 30, 2025$9M141.5%$-0.49−$41M
March 31, 2025$3M5.0%$-0.45−$31M
December 31, 2024$3M−35.6%$-0.46−$22M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

41 ledger entries and 44 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.